Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT06512961
Enrolling by invitation Not applicable

Applicability of Tissue Flossing for Blood Flow Restriction in the Upper Limb: Reliability and Performance Analysis

NCT06512961 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2025-08-01
Last updated
2026-09-18

Condition(s) studied

HypertrophyMuscle Strength

Investigational drug(s) / intervention(s)

Tissue FlossingBlood Flow Restriction CuffTraining Protocol

Tissue Flossing: Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.

Blood Flow Restriction Cuff: Inflatable device that exerts an external pressure above a muscle or joint of the extremities.

Training Protocol: The upper limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 15weeks, with 3 training sessions per week, with a day break between sessions.

Study summary

Blood flow restriction (BFR) is a widely studied technique that combines low-intensity exercise with vascular occlusion, resulting in muscular benefits. However, its application is challenging due to methodological variations and equipment costs. Tissue Flossing (TF) appears as an affordable alternative, but lacks solid scientific evidence.

Eligibility

Sex
MALE
Min age
18 Years
Max age
30 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals who present one or more of the following characteristics will not be included: * 1 presence of any health condition that contraindicates or prevents exercise; * 2 diabetes and diagnosed high blood pressure; * 3 inflammatory, psychiatric, cardiovascular and/or respiratory rheumatological disease; - -4 being dependent on alcohol, consuming drugs and/or being a smoker; * 5 history of knee surgery (e.g., meniscal repair and ligament reconstruction) or recent upper limb musculoskeletal injury that may impair performance during tests or interventions (e.g., muscle injury, tendinopathy, patellofemoral pain and/or back pain column in the last six months); * 6 use of ergogenic supplements to improve physical performance and/or muscle mass and/or vasoactive medications; * 7 having one or more risk factors predisposing to thromboembolism Exclusion Criteria: * Participants will be excluded from the study if they: * 1 have a health problem that does not allow them to continue; * 2 wish to leave the study; * 3 not sign the consent form

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
UNESP Presidente Prudente São Paulo

More Paulista University trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06512961 on ClinicalTrials.gov ↗ ← All trials in Brazil